#United States #Pittsburgh #Business Performance #Viatris #Financial Update

Viatris Reports Strong Third Quarter 2025 Results

Viatris Inc. (Nasdaq: VTRS) recently announced impressive third-quarter 2025 results that align with market expectations, showcasing the company's robust execution across its global operations. Alongside this performance, Viatris updated its financial guidance for the remainder of the year.

Financial Performance Highlights

During the third quarter of 2025, Viatris achieved total revenues of $3.76 billion, reflecting a stable performance relative to the same period last year. Despite some headwinds, particularly from divestitures and foreign exchange fluctuations, the company managed to raise and narrow its financial guidance for total revenues, adjusted EBITDA, and adjusted EPS. CEO Scott A. Smith highlighted this achievement as a testament to the strength of the execution by the Viatris team amidst challenging market conditions.

Key Figures:

• - Total Revenues: $3.76 billion
• - Net Earnings: $(128) million, down from $95 million last year
• - Adjusted EPS: $0.67 per share
• - Adjusted EBITDA: $1.15 billion

Business Developments and Strategic Investments

Viatris is actively advancing its product pipeline. Notably, the company made significant progress towards securing regulatory approvals for new products, including a low-dose estrogen weekly patch recently submitted to the FDA, with anticipated approval in mid-2026. Moreover, they completed the acquisition of Aculys Pharma, gaining exclusive rights to Pitolisant and Spydia® in Japan, aiming to expand their market reach in Asia.

The acquisition is seen as a strategic move to enhance Viatris' portfolio and cement its competitive edge within the biopharmaceutical market. In terms of capital allocation, Viatris has been proactive in returning capital to its shareholders, having already returned over $920 million year-to-date, including $500 million in share repurchases.

Growth Amid Challenges

Despite a net loss reported due mainly to impairments and increased tax expenses, the company's operational performance remains strong. Adjusted measures showcase the underlying health of the business, which include:

• - Adjusted Gross Profit: $2.10 billion
• - Adjusted Gross Margin: 56.0%

Continued strong sales in Greater China and Emerging Markets have mitigated some of the financial impacts from mature markets facing challenges. This operational resilience underlines the company's strategic objectives moving forward.

Future Outlook

Viatris is preparing for an Investor Event in early 2026 to discuss the strategic direction and provide insights into the enterprise-wide strategic review which was initiated earlier this year. As the company seeks sustainable growth into 2026 and beyond, they are looking at potential efficiencies in operations, RD, and corporate functions, all aimed at enhancing profitability.

The adjustments made in financial metrics highlight Viatris’ commitment to enhancing shareholder value amidst a dynamic and sometimes unpredictable healthcare landscape. The outlook for the rest of 2025 remains cautiously optimistic, underscored by the confidence in their product pipeline and market positioning.

As Viatris continues to progress with its strategic initiatives, it reaffirmatively stands at the forefront of bridging the gap between generic and branded pharmaceutical markets, thus addressing the healthcare needs of patients globally. With extensive experience and a broad product range, Viatris is well-equipped to tackle the challenges of the future while delivering significant value to its stakeholders.

In conclusion, the recent results exhibit Viatris' capability to navigate complex market dynamics effectively while maintaining a clear focus on strategic growth initiatives, promising advancements in product development, and robust shareholder returns.